How the lab is changing our view of colorectal cancer

被引:8
作者
Cremolini, Chiara [1 ]
Pietrantonio, Filippo [2 ]
机构
[1] Univ Pisa, Dept Oncol, Univ Hosp Pisa, Tuscan Tumor Inst, Pisa, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
来源
TUMORI JOURNAL | 2016年 / 102卷 / 06期
关键词
Biomarkers; Colorectal cancer; Precision medicine; FOLFOXIRI PLUS BEVACIZUMAB; PHASE-II; MICROSATELLITE INSTABILITY; PREDICTIVE BIOMARKER; 1ST-LINE TREATMENT; ANTIBODY THERAPY; BRAF MUTATION; IMMUNE CELLS; TEMOZOLOMIDE; GENE;
D O I
10.5301/tj.5000551
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In metastatic colorectal cancer, the optimization of upfront treatment and the continuum of care based on patients' exposure to multiple treatment lines have reached a plateau of efficacy. Therefore, a paradigm shift is ongoing towards precision medicine and personalized treatments based on the specific molecular features of the disease. In this perspective, the improved knowledge of disease biology coming from the lab has prompted a rapid translation from bench to bedside of newer targeted strategies. Here, we focus on the most promising biomarkers already included or close to adoption in daily clinical practice. In particular, evidence about the potential roles of BRAF mutation, HER2 amplification, MGMT methylation, microsatellite instability, and ALK, ROS and NTRK1-3 rearrangements as positive predictors of benefit from biological agents is reviewed and discussed.
引用
收藏
页码:541 / 547
页数:7
相关论文
共 70 条
  • [1] ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
    Aisner, Dara L.
    Nguyen, Teresa T.
    Paskulin, Diego D.
    Le, Anh T.
    Haney, Jerry
    Schulte, Nathan
    Chionh, Fiona
    Hardingham, Jenny
    Mariadason, John
    Tebbutt, Niall
    Doebele, Robert C.
    Weickhardt, Andrew J.
    Varella-Garcia, Marileila
    [J]. MOLECULAR CANCER RESEARCH, 2014, 12 (01) : 111 - 118
  • [2] Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
    Amatu, A.
    Barault, L.
    Moutinho, C.
    Cassingena, A.
    Bencardino, K.
    Ghezzi, S.
    Palmeri, L.
    Bonazzina, E.
    Tosi, F.
    Ricotta, R.
    Cipani, T.
    Crivori, P.
    Gatto, R.
    Chirico, G.
    Marrapese, G.
    Truini, M.
    Bardelli, A.
    Esteller, M.
    Di Nicolantonio, F.
    Sartore-Bianchi, A.
    Siena, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (06) : 1062 - 1067
  • [3] Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
    Amatu, Alessio
    Somaschini, Alessio
    Cerea, Giulio
    Bosotti, Roberta
    Valtorta, Emanuele
    Buonandi, Pasquale
    Marrapese, Giovanna
    Veronese, Silvio
    Luo, David
    Hornby, Zachary
    Multani, Pratik
    Murphy, Danielle
    Shoemaker, Robert
    Lauricella, Calogero
    Giannetta, Laura
    Maiolani, Martina
    Vanzulli, Angelo
    Ardini, Elena
    Galvani, Arturo
    Isacchi, Antonella
    Sartore-Bianchi, Andrea
    Siena, Salvatore
    [J]. BRITISH JOURNAL OF CANCER, 2015, 113 (12) : 1730 - 1734
  • [4] Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer
    Amatu, Alessio
    Sartore-Bianchi, Andrea
    Moutinho, Catia
    Belotti, Alessandro
    Bencardino, Katia
    Chirico, Giuseppe
    Cassingena, Andrea
    Rusconi, Francesca
    Esposito, Anna
    Nichelatti, Michele
    Esteller, Manel
    Siena, Salvatore
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2265 - 2272
  • [5] [Anonymous], J CLIN ONCOL S5S
  • [6] Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
    Barault, L.
    Amatu, A.
    Bleeker, F. E.
    Moutinho, C.
    Falcomata, C.
    Fiano, V.
    Cassingena, A.
    Siravegna, G.
    Milione, M.
    Cassoni, P.
    De Braud, F.
    Ruda, R.
    Soffietti, R.
    Venesio, T.
    Bardelli, A.
    Wesseling, P.
    Hamer, P. de Witt
    Pietrantonio, F.
    Siena, S.
    Esteller, M.
    Sartore-Bianchi, A.
    Di Nicolantonio, F.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (09) : 1994 - 1999
  • [7] Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
    Bendell, Johanna C.
    Kim, Tae Won
    Goh, Boon C.
    Wallin, Jeffrey
    Oh, Do-Youn
    Han, Sae-Won
    Lee, Carrie B.
    Hellmann, Matthew David
    Desai, Jayesh
    Lewin, Jeremy Howard
    Solomon, Benjamin J.
    Chow, Laura Quan Man
    Miller, Wilson H.
    Gainor, Justin F.
    Flaherty, Keith
    Infante, Jeffrey R.
    Das-Thakur, Meghna
    Foster, Paul
    Cha, Edward
    Bang, Yung-Jue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
    Bendell, Johanna C.
    Atreya, Chloe Evelyn
    Andre, Thierry
    Tabernero, Josep
    Gordon, Michael S.
    Bernards, Rene
    Van Cutsem, Eric
    Tejpar, Sabine
    Sidhu, Roger
    Go, William Y.
    Allred, Alicia
    Motwani, Monica
    Suttle, Benjamin B.
    Wu, Yuehui
    Hoos, Axel
    Orford, Keith W.
    Corcoran, Ryan Bruce
    Schellens, Jan H. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
    Bertotti, Andrea
    Migliardi, Giorgia
    Galimi, Francesco
    Sassi, Francesco
    Torti, Davide
    Isella, Claudio
    Cora, Davide
    Di Nicolantonio, Federica
    Buscarino, Michela
    Petti, Consalvo
    Ribero, Dario
    Russolillo, Nadia
    Muratore, Andrea
    Massucco, Paolo
    Pisacane, Alberto
    Molinaro, Luca
    Valtorta, Emanuele
    Sartore-Bianchi, Andrea
    Risio, Mauro
    Capussotti, Lorenzo
    Gambacorta, Marcello
    Siena, Salvatore
    Medico, Enzo
    Sapino, Anna
    Marsoni, Silvia
    Comoglio, Paolo M.
    Bardelli, Alberto
    Trusolino, Livio
    [J]. CANCER DISCOVERY, 2011, 1 (06) : 508 - 523
  • [10] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Karbownik, Malgorzata
    Migdalska-Sek, Monika
    Pastuszak-Lewandoska, Dorota
    Wloch, Jan
    Lewinski, Andrzej
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) : 26 - 35